SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. (&#34;Modular Medical&#34; or the &#34;Company&#34;) (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received

<p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 16, 2026 / </strong>Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.</p><p><strong>About Modular Medical</strong></p><p>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."</p><p>Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at <a rel="nofollow" href="https://protect.checkpoint.com/v2/r01/___https:/pr.report/NyQvWeDS___.YXAzOm1vZHVsYXItbWVkaWNhbDpjOm86MmQwYWQ5YTU1YjMyNTE4ZmIzOWJiMTNlYTlmOTkwYzU6NzozNGI4OjI2MTFkNzY0OTRlY2Y0ODgyN2FkZDQ1MzhlZGU1YTcxYjMzZGEwNzVlMDkxZjYxZTExNzFiNjY0N2M2ZmQyMzE6cDpUOk4">https://modular-medical.com</a>.</p><p><strong>CONTACT:</strong><br/>Jeb Besser<br/>Chief Executive Officer<br/>Modular Medical, Inc.<br/>+1 (617) 399-1741<br/><a rel="nofollow" href="mailto:IR@modular-medical.com">IR@modular-medical.com</a></p><p><strong>SOURCE: </strong>Modular Medical, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-regains-compliance-with-nasdaq-minimum-bid-price-requ-1158188'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1158188" width="0" height="0"/>

MODD

Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Modular Medical Regains Nasdaq Compliance with Minimum Bid Price Requirement

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. (&amp;#34;Modular Medical&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Modular Medical has successfully regained compliance with Nasdaq&#039;s minimum bid price requirement as of April 14, 2026. This compliance reflects positive market perception and could stabilize the stock price, potentially attracting new investors.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Modular Medical regained Nasdaq compliance as of April 14, 2026.</li><li>The stock has maintained prices above $1 for 10 consecutive days.</li><li>Company focuses on innovative insulin delivery technologies.</li><li>Modular Medical aims to simplify diabetes care accessibility.</li><li>Past founder of Tandem Diabetes leads the company.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Tandem Diabetes (TNDM)</strong>: Experience from Tandem Diabetes strengthens Modular Medical&#039;s innovative development potential.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits within &#039;Corporate Developments&#039; as it marks a significant operational milestone for Modular Medical, enhancing its credibility and market position amidst competitive pressures in the diabetes care space.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regaining Nasdaq compliance may increase investor confidence in Modular Medical.</li><li>Stock price stability over $1 could attract institutional investment.</li><li>Company&#039;s innovative approach to insulin delivery presents growth potential.</li><li>Leadership experience from Tandem Diabetes may accelerate product development.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Regained compliance notification received on April 16, 2026.</li><li>Closing bid price above $1 for 10 consecutive trading days.</li><li>Company aims to launch next-gen insulin delivery technology.</li><li>Founded by Paul DiPerna, ex-founder of Tandem Diabetes.</li><li>Focus on affordable and simple diabetes care solutions.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in MODD with a bullish outlook as compliance enhances credibility; short-term catalyst.</p>
  </section>
</section>


<p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 16, 2026 / </strong>Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.</p><p><strong>About Modular Medical</strong></p><p>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."</p><p>Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at <a rel="nofollow" href="https://protect.checkpoint.com/v2/r01/___https:/pr.report/NyQvWeDS___.YXAzOm1vZHVsYXItbWVkaWNhbDpjOm86MmQwYWQ5YTU1YjMyNTE4ZmIzOWJiMTNlYTlmOTkwYzU6NzozNGI4OjI2MTFkNzY0OTRlY2Y0ODgyN2FkZDQ1MzhlZGU1YTcxYjMzZGEwNzVlMDkxZjYxZTExNzFiNjY0N2M2ZmQyMzE6cDpUOk4">https://modular-medical.com</a>.</p><p><strong>CONTACT:</strong><br/>Jeb Besser<br/>Chief Executive Officer<br/>Modular Medical, Inc.<br/>+1 (617) 399-1741<br/><a rel="nofollow" href="mailto:IR@modular-medical.com">IR@modular-medical.com</a></p><p><strong>SOURCE: </strong>Modular Medical, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-regains-compliance-with-nasdaq-minimum-bid-price-requ-1158188'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1158188" width="0" height="0"/>

Modular Medical has successfully regained compliance with Nasdaq's minimum bid price requirement as of April 14, 2026. This compliance reflects positive market perception and could stabilize the stock price, potentially attracting new investors.

Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News